Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Retained Earnings (2023 - 2026)

Prelude Therapeutics' Retained Earnings history spans 4 years, with the latest figure at -$693.4 million for Q1 2026.

  • On a quarterly basis, Retained Earnings fell 12.64% to -$693.4 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$693.4 million, a 12.64% decrease, with the full-year FY2025 number at -$683.1 million, down 1951702.86% from a year prior.
  • Retained Earnings hit -$693.4 million in Q1 2026 for Prelude Therapeutics, down from -$683.1 million in the prior quarter.
  • Over the last five years, Retained Earnings for PRLD hit a ceiling of $35000.0 in Q4 2024 and a floor of -$693.4 million in Q1 2026.
  • Historically, Retained Earnings has averaged -$413.8 million across 4 years, with a median of -$521.3 million in 2024.
  • Biggest five-year swings in Retained Earnings: soared 100.01% in 2024 and later tumbled 1951702.86% in 2025.
  • Tracing PRLD's Retained Earnings over 4 years: stood at -$456.4 million in 2023, then soared by 100.01% to $35000.0 in 2024, then tumbled by 1951702.86% to -$683.1 million in 2025, then decreased by 1.51% to -$693.4 million in 2026.
  • Business Quant data shows Retained Earnings for PRLD at -$693.4 million in Q1 2026, -$683.1 million in Q4 2025, and $2000.0 in Q3 2025.